Abstract
Background Whilst anti-coagulation is typically recommended for thromboprophylaxis in atrial fibrillation (AF), it is often never prescribed, or prematurely discontinued, due to concerns regarding bleeding risk. The aim of this study was to assess both stroke/systemic embolism (SSE) and bleeding risk, comparing people with AF who continue anticoagulation with those who stop transiently, stop permanently or never start.
Methods This retrospective cohort study utilised linked Scottish administrative healthcare data to identify adults diagnosed with AF between January 2010 and April 2016, with a CHA2DS2- VASC score of ≥2. They were sub-categorised into cohorts based on anti-coagulant exposure: never started, continuous, discontinuous, and cessation. Inverse probability of treatment weighting-adjusted Cox regression and competing-risks regression were utilised to compare the risks of SSE and major bleeding between cohorts during a five year follow-up period. Sub-group analyses evaluating risk of SSE, bleeding and mortality, were undertaken for people commenced on anti-coagulation that experienced a major bleeding event
Results Of an overall cohort of 47,427 people, 26,277 (55.41%) were never anti-coagulated, 7,934 (16.72%) received continuous anti-coagulation, 9,107 (19.2%) temporarily discontinued and 4,109 (8.66%) permanently discontinued. Initiation and continuation of anti-coagulation was less likely in people with a lower socio-economic status, elevated frailty score, or aged ≥75. SSE risk was significantly greater in those with discontinuous anti-coagulation, compared to continuous (SHR: 2.65; 2.39-2.94). In the context of a major bleeding event, there was no significant difference in bleeding risk between the cessation cohort compared to those that continued anti-coagulation (SHR 0.94; 0.42-2.14).
Conclusion Our data suggest significant inequalities in anti-coagulation prescribing for people with AF, with substantial opportunity to improve initiation and continuation. Anti-coagulation decision-making must be patient-centered and recognise that discontinuation or cessation is associated with a substantial risk of thromboembolic events not offset by a reduction in bleeding.
Despite a high thromboembolic risk, anti-coagulation in people with atrial fibrillation is frequently not initiated, or prematurely discontinued
Our data suggest considerable inequalities in anti-coagulation prescribing in people with atrial fibrillation; people with a lower socio-economic status, elevated frailty score, or aged ≥75 were less likely to initiate or continuation anti-coagulation
Whilst non-initiation and cessation of anti-coagulation are associated with elevated thromboembolic risk, this risk is particularly high in people with atrial fibrillation that transiently discontinue anti-coagulation
In the context of a major bleeding event, permanent discontinuation of anti-coagulation in people with atrial fibrillation is not associated with a significantly reduced risk of recurrent bleeding compared to those that are continuously anti-coagulated.
Competing Interest Statement
RM, FM, GC, TQ, and CG have received research grants from Bristol Myers Squibb and Pfizer UK. RT is currently employed by Pfizer UK. KP is currently employed by Bristol Myers Squibb. SL was previously employed by Bristol Myers Squibb.
Funding Statement
This study was sponsored by Pfizer and Bristol Myers Squibb. Employees of the respective funding bodies were involved in the design of the study, writing of the manuscript, and decision-making regarding publication of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study, using only de-identified data collected in Scottish clinical routine, did not require review and approval by an NHS Research Ethics Committee. A data plan was submitted to University of Glasgow, School of Medical, Veterinary and Life Sciences Ethics Committee, who granted a favourable opinion.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
